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Summary: The mechanism of the depletion of several plasma amino acids in 
PKU has remained unexplained. In the present study, a statistically significant 
decrease in the plasma concentration of several amino acids was observed 2 h 
after the intraperitoneal injection of Phe to weanling rats. The pattern was 
very similar to the one observed in PKU patients. Statistically significant 
increases in the distribution ratios liver/plasma and, mainly, muscle/plasma 
ratios accompanied in most of the cases the corresponding decreases in plasma 
concentrations. Equimolar injection under the same conditions of the non- 
insulinogenic transport system L analogue, the a(+) isomer of the 2-amino- 
norbornane-2-carboxylic acid, produced, in a parallel effect to Phe, statisti- 
cally significant increases in the distribution ratios of Ala and Gly, and 
probably of Pro in muscle, as well as of Ala in liver. These results seem to 
indicate that the high intracellular Phe attained inhibits the exodus of small 
neutral amino acids through system L, causing their depletion in plasma and 
ultimately in the brain. This effect may be additive to the inhibition by Phe 
of the entry of bulky neutral amino acids at the level of the blood-brain 
barrier. Further study is needed to assess the relevance of these effects to 
PKU. 
The underlying pathogenetic mechanism that leads to mental retardation in phenyl- 
ketonuria (PKU) is not known (Scriver and Clow, 1980). An inadequate supply of 
certain amino acids to the brain with the ensuing impairment of protein and/or 
neurotransmitter synthesis is likely to be a major factor contributing to the brain 
damage (Tourian and Sidbury, 1983). 
In 1953, one of us (H.N.C.) predicted that the systemic accumulation of phenylal- 
anine in PKU might interfere with the  transport of several amino acids into the 
brain. This hypothesis has received strong support. Depletion of amino acids in the 
brain has been observed in animals with experimental hyperphenylalaninaemia 
(McKean et al., 1968) and at autopsy of PKU patients (McKean, 1972). Inhibition 
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of influx of amino acids into the brain has been also observed in similar animal 
models (Partridge and Oldendorf, 1977), along with transport-competitive effects 
of phenylalanine in isolated human brain capillaries (Choi and Partridge, 1986). 
In general, the bulky neutral amino acids are mainly affected by Phe, a result that 
indicates that the inhibitory effect may occur at the level of transport system L in 
the blood-brain barrier (Wade and Katzman, 1975; Betz and Goldstein, 1978). 
An accompanying paradox has received less attention. The plasma concentrations 
of several dipolar amino acids, the large ones less generally affected, decrease in 
plasma in PKU patients (Linneweh and Ehrlich, 1962; Efron et al., 1969). The 
mechanism of this change is not known; malnutrition and loss in the urine have 
been excluded as possible explanations; decreased intestinal absorption or loss into 
the gut lumen is unlikely (Efron et al., 1969). 
Huether and colleagues (1984) have reported accumulation of several amino 
acids in various non-brain tissues of newborn rats chronically treated with phenylal- 
anine and a-MePhe. The mechanism of this accumulative effect has likewise not 
been explained. 
It was observed some years ago in this laboratory that the muscle/plasma ratio 
(Christensen et al,,, 1948) or liver/plasma ratio (Christensen and Cullen, 1981) of 
some amino acids increase, rather than decrease, in the presence of certain system 
L substrates or analogues. The most likely explanation for this effect was taken to 
be an inhibitory action of the analogues on the exodus of the affected amino acids 
from tissues through system L. These observations have led Christensen to propose 
that the depletion of some plasma amino acids in PKU may be explained as a 
sequestering effect of Phe by a similar inhibition of the exodus of certain amino 
acids from non-brain tissues, causing their sequestration and possible accelerated 




L-Phenylalanine was obtained from SIGMA. The racemic aminoexo isomer of the 2- 
aminonorbornane-2-carboxylic acid, often designated as a(+)B CH, but abbreviated 
here as aBCH, was our own preparation (Tager and Christensen, 1972). Aspartame 
was provided to us by the NutraSweet Company. All other reagents were of the 
best grade commercially available. 
Animals 
Twenty-two-day-old Sprague-Dawley male weanling rats, weighing 38-66 g were 
used for all the experiments. Rats were fasted for 20-24 h before each experiment. 
Procedure 
Phe or aBCH was injected intraperitoneally as an iso-osmotic solution at a d o s e o f  
10mmol/kg body weight. Control rats received an intraperitoneal injection of 
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0.85 % NaC1 in the corresponding volume. Aspartame was administered by stomach 
tube only partially dissolved as a slurry, 1.5 g per kg, in 15 ml water. Two hours 
after an administration, the rats were anaesthetized with ether. Blood was taken 
from the exposed heart and collected in a heparinized tube. Plasma was separated 
and deproteinized with an equal volume of 12% sulphosalicylic acid" Approxi- 
mately 1 g of liver and 0.5 g of muscle from the left thigh were weighed and ground 
in a mortar with sand and a 10% solution of sulphosalicylic acid in a volume 4 
times the fresh weight of the tissue in grams. The homogenate was filtered through 
Whatman 4#1 paper. The protein-free filtrate was stored at -20°C until analysis. 
Analysis 
Amino acids were measured with a 119 CL Beckman automatic amino acid analyser 
using a high-sensitivity amino acid standard solution from SIGMA. 
Calculations 
For calculation of apparent concentrations of amino acids in cell water, the liver 
and muscle samples were taken to contain, respectively, 49% and 62% intracellular 
and 22% and 15% extracellular water (Christensen and Cullen, 1981; Lowry and 
Hastings, 1942). The distribution ratio, tissue/plasma, was the ratio ~tmol kg -1 cell 
water/~tmolkg -I extracellular water (Lowry and Hastings, 1942). 
Statistical analysis 
Differences in plasma levels, intracellular concentrations and distribution ratios 
between Phe- or aBCH-treated and control rats were calculated by the t test using 
separate variances when the number of controls and treated animals differed 
(Wilkinson, 1986). 
RESULTS 
Plasma levels of Phe and tyrosine at various intervals after Phe injection are shown 
in Figure 1. Maximum levels of Phe, about 40 times the levels of the controls, were 
observed at 2h, although about 75% of the increase was seen by 30 min. By 4h, a 
75% decline from the peak was observed, and, by 8 h, the levels had returned to 
control values. Presumably through the action of the uninhibited hepatic hydroxy- 
lase, Tyr increased, although at a slower rate than Phe, during the first 2h, 
increasing further as Phe decreased. On the basis of these results, all subsequent 
experiments were performed taking the samples at 2h after injection. 
Plasma amino acid levels and net intracellular concentrations in liver and muscle 
after Phe injection are shown in Table 1. There was a statistically significant increase 
in the plasma concentrations of both Phe and Tyr; the ratio [Phe]/[Tyr] at 2 h was 
about 8/1. All other amino acids except Glu- showed decreased plasma levels 2h 
after Phe administration, the difference being statistically significant for Leu; lie, 
Ala, Pro, Gly, His, Orn and Arg. The valine decrease showed a p value of 0.055 
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Figure 1 Time course of Phe and Tyr plasma levels after Phe administration. Each pair of 
points represents one animal. Values at 0 and 2 h in the same range of the means found in 
further experiments 
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Table 1 Plasma and net intracellular amino acid concentrations in controls and after Phe 
administration (for details see Experimental procedures). Values are means---S.D., n=8 
controls, 8 experimental animals. Plasma and tissue levels are expressed in ~tmol/L and 
Itmol/kg tissue, respectively 
Plasma Liver Muscle 
Control + Phe Control + Phe Control + Phe 
Phe 104+28 4421_+868" 6 0 _ + 3 9  1348+786"* 138_+73 3560+670* 
Tyr 93_+23 537_+108" 3 9 _ + 2 1  327+106" 1 2 4 _ + 4 7  509+117" 
Trp 116_+27 103_+34 42+39 56_+32 67_+44 94_+83 
Leu 254_+27 139-+37" 151-+89 1 3 4 + _ 3 8  2 2 8 _ + 9 1  198_+77 
Ileu 175+37 105_+327 53+-50 61_+28 1 8 0 _ + 6 3  141-+61 
Val 332_+49 268_+717% 209_+128 1 8 4 _ + 6 5  2 8 5 _ + 1 0 6  257-+84 
Ala 419-+120 219+-1287 1056_+494 1756_+674"* 1897_+1369 2261_+1481 
Pro 188_+38 99-+42? 67_+60 77_+37 367+103 644-+318"* 
Gly 625-+121 391_+1347 2392_+1127 2381_+680 5287_+3030 6807_+3921 
His 83_+20 59+117 376-+224 377-+137 369-+102 428-+94 
Orn 82_+23 53_+27** 233_+118 193+66 2 8 5 _ + 9 1  316_+134 
Arg 167_+26 100_+21" N.D. N.D. 1029_+319 1018_+108 
Lys 436+-176 317_+146 403_+361  439_+181 3166+_1380 2877_+1587 
Gin 6 0 8 _ + 1 9 5  471_+186 1728_+848 1013_+532 3853_+2792 3642+_2051 
Glu 184_+61 226_+195  1592_+1030 1548+_688 2172_+637 2933_+614"* 
*p<0.001; ?p<0.01; **p = <0.05; ??p = 0.055; N.D. = undetectable by the analysis used 
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(Table 1). In general, the amino acid pattern in plasma was very similar to the one 
reported by Linneweh and Ehrlich (1962) and Efron and colleagues (1969) in PKU 
children (Figure 2). 
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Figure 2 Plasma amino acid levels after Phe administration in rats and in PKU children 
off treatment. Plasma concentrations from Table 1 and from Linneweh and Ehrlich (1962) 
and Efron and colleagues (1969) are shown here as per cent of control. Non-essential amino 
acids were not included in the statistical calculations in Linneweh and Ehrlich. The one- 
letter abbreviations are Glu, E; Trp, W; Val, V; Gln, Q; Lys, K; His; H; Gly, G; Ileu, I; 
Leu, L; Pro; P; Ala,  A; Thr, T; Arg,  R 
Statistically significant increases in net intracellular concentrations were found 
for Phe and Tyr in both organs studied (Table 1); the ratio [Phe]/[Tyr] reached at 
2 h was 4/1 and 7/1 in liver and muscle, respectively. In liver, aside from Phe and 
Tyr, Ala was the only amino acid that showed a statistically significant increase in 
net intracellular concentration. In muscle, only Pro and Glu- showed statistically 
significant increases in their net intracellular concentrations (Table 1). 
Amino acid distribution ratios, liver/plasma and muscle/plasma, after Phe injec- 
tion are shown in Table 2. Owing to the extremely high plasma levels attained, 
hepatic Phe showed an almost statistically significant decrease in its distribution 
ratio in spite of the high intracellular concentration reached (p = 0.051). All other 
amino acids except Glu- showed an increase in their distribution ratio in liver, 
although the difference was statistically significant only for Ala, Gly and Lys (Table 
2, column 3). 
In muscle, both Phe and Tyr showed decreases in their distribution ratios after 
Phe injection, but the difference was statistically significant only for Tyr. All 
other amino acids showed increases in their distribution ratios; the difference was 
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Table 2 Changes in relative concentrations and distribution of each of 15 amino acids 
produced after injecting L-Phe or aBCH into weanling rats 
Phe injection aBCH injection 
Plasma Liver Muscle Plasma Liver Muscle 
Phe 4300* 2250t 2580* 124 105 109 
D.R. 0.50 0.62 1.09 0.84 
Tyr 580* 840* 410" 99 82 93 
D.R. 1.41 0.72? 1.18 1.03 
Trp 89 133 140 
D.R. 1.52 1.34 
Leu 55* 89 87 121 84 93 
D.R. 1.31 1.56? 1.06 0.88 
Ileu 60** 115 78 108 68 89 
D.R. 2.19 1.29 1.03 0.84 
Val 81 88 90 113 71 92 
D.R. 1.24 1.25 1.01 1.19 
Ala 52** 167t 119 91 92 101 
D.R. 3.74** 2-62? 1.53t? 1.68t 
Pro 53** 115 175t 90 80 102 
D.R. 2.19 3.93* 0.56 1.32 
Gly 63** 100 129 71? 70** 107 
D.R. 1.88t 2.187 1.05 1.80"* 
His 71"* 100 116 126 85 87 
D.R. 1.50 1.567 0.84 0.76 
Orn 65t 83 111 94 77 79 
D.R. 1.50 1.88"* 1.07 0.98 
Arg 60* Not 99 99 Not 120 
D.R. detected 1.98"* detected 1.20 
Lys 73 109 90 101 114 99 
D.R. 1.87? 1.30 1.58 0,92 
Gln 77 58 95 
D.R. 1.10 1.34 
Glu 124 97 135t 
D.R. 1.03 1.62 
The 3 values in each column parallel with the abbreviation (Column 1) of the amino acids 
show, for plasma, liver and muscle, respectively, the percentage of the control value attained 
in 2 h for each of these tissues. The number just below the percentage value for each amino 
acid shows the calculated relative distribution ratio (D.R.) between the concentrations in 
the cellular and extracellular water, as described under Methods, for the indicated solid 
tissue. The number of animals represented by each value varies from 7 to 13, both for 
control and experimental groups. See Tables 1 and 3 for the analytically determined 
cor~centrations which served for calculating these amino acid distributions. The superscript 
symbols indicate the statistical significance of changes 
*p<0.001, **p<0.01, tp<0.05, ttp<0.07 
statistically significant for Leu, Ala, Pro, Gly, His, Orn and Arg (Table 2, column 
4). 
Parallel experiments to those with Phe were made with aBCH (Table 2). This 
isomer of BCH was selected because it is not an insulin secretagogue (Tager and 
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Christensen, 1971) and could serve to dissociate that action from the suspected 
direct effects on amino acid transport. 
Gly showed a statistically significant decrease in both plasma and liver concen- 
Table 3 Plasma and net intracellular amino acid concentrations in controls and after aBCH 
administration (for details see Experimental procedures). Values are means±S.D.; n=5 
controls, 7 experimental animals. Plasma and tissue levels are expressed in ~tmol/L and 
~tmoFkg tissue, respectively 
Plasma Liver Muscle 
Control +aBCH Control +aBCH Control +aBCH 
Phe 72+14 89+22 61_+12 64+12 96_+22 102_+22 
Tyr 71+18 70_+21 56+16 46_+10 118_+26 106_+21 
Leu 224-+65 271_+119 265-+84 223_+59 249_+94 231_+84 
[leu 309_+274 335_+306 142+86 97-+58 220_+145 196+105 
Val 206+44 230+89 258+61 183+71 250_+59 230+59 
Ala 318+50 289+_93 1605+_555 t470-+445 3107+_961 3145+715 
Pro 156+28 141-+40  1 4 6 + 1 0 3  1 1 6 + 6 8  378+123  385-+178 
Gly 5 5 6 + 1 0 6  393+-108? 2882_+43 2019+535" 6755+_1626 7243+_1646 
His 65_+26 82+_18 510_+79 432+115  394-+109 342_+60 
Orn 52_+17 49+17 269+-58 202_+36 260-+117 206+68 
Arg 138_+16 133+38 N.D. N.D. 684_+242 822_+221 
Lys 402_+170 405+-145 788+-426 895_+431 3162_+1031 3138+949 
*p<0.01; fp<0.05; N.D. = undetectable by the analysis used 
trations after aBCH injection (Table 3). With the exception of Ala, Gly, Pro 
and Arg in muscle, there was a tendency of most amino acids to be decreased 
intracellularly after aBCH injection in both organs studied. In no case, however, 
were the changes statistically significant (Table 3). 
Ala showed an increase in its liver/plasma distribution ratio after aBCH injection 
on the verge of statistical significance (p = 0.07). In no case were the changes in 
distribution ratios, if any, for other amino acids in liver statistically significant 
(Table 2, column 6). 
Ala and Gly showed statistically significant increases in their muscle/plasma 
distribution ratios after the administration of aBCH. Pro, although the amino acid 
whose distribution ratio increased the most next to Ala and Gly (Figure 3, panel 
D), showed a p value of 0.2 for the increase in its muscle/plasma distribution ratio. 
The combined distribution ratios, muscle/plasma of the three small neutral amino 
acids, showed, however, a statistically significant difference when considered collec- 
tively (Figure 3). Despite the considerable variance, we find the general downward 
trends impressive. 
Aspartame administered by stomach tube as a 10% slurry in a dose of 1.5 g per 
kg body weight, approximately equivalent to the phenylalanine injected, led, in 
2 h (4 animals), to increases of the plasma phenylalanine by about four-fold, to 
0.2mmol/L, and of the tyrosine as a significant contrast by about ten-fold, to 
0.5 mmol/L. Several of the same amino acids lowered in the plasma by phenylalan- 
ine (e.g Gly, Pro, Met, Arg, Val) tended downward. Observations On one animal 
J. Inher. Metab. Dis. 12 (1989) 
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Figure 3 Distribution ratios muscle/plasma for the small neutral amino acids, Ala, Pro 
and Gly, after aBCH administration. Results are expressed as per cent of control; n varied 
from 7 to 13 animals for both control and experimental observations 
each at 1 and 1.5 h already indicated the same tendencies. Because of the compli- 
cations of interpretation arising from possible effects of aspartate released from 
aspartame (e.g. distinct rises seen for plasma Ala and Gln), we did not, in this 
case, extend our results to the point of general statistical significance for the declines 
in plasma animo acid levels. 
DISCUSSION 
We lack an animal model to represent PKU and the usual experimental approach 
by inducing h1~erphenylalaninaemic states in rats has important drawbacks. Phe 
administered chronically results in a higher concentration of Tyr in plasma, an 
effect opposite to the change observed in the human disease. Inhibitors of Phe 
hydroxylase, in particular p-C1Phe, are not entirely specific and show considerable 
toxicity manifested as loss of weight and high mortality (Vorhees et at., 1981). 
Therefore, we used no inhibitor of the hydroxylase in the present study. Under our 
experimental conditions, statistically significant increases in the concentration of 
Phe in plasma and tissues were nevertheless obtained. Although Tyr also increased 
significantly in plasma and tissues, the mean [Phe]/[Tyr] ratios were 8/1, 4/1, and 
7/1 in plasma, liver and muscle, respectively (Table 1). Moreover, the statistically 
significant decrease of the muscle/plasma ratio for Tyr (Table 2, column 4), 
consistent with the slower rise in plasma Tyr concentration than Phe (Figure 1), 
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indicates that, at least in muscle, Tyr had not yet attained a steady-state distribution 
by the time our experiments were terminated. Therefore,  we believe that the effects 
observed here were caused mainly by elevation of Phe and not of Tyr. 
From previous work in this laboratory, we have learned that, under normal 
conditions, changes in amino acid concentrations in plasma and tissues tend to go 
in the same direction (Christensen et al., 1948). Only when selective inhibitors e.g. 















Figure 4 Diagram to illustrate the parallel operation of two transport systems in non-brain 
tissues. The Na+-dependent systems, such as A, tend to be highly concentrative for G, so 
that Na+-independent, system L is caused to serve mainly for its exodus. G may represent 
Gly, Ala or Pro in this study, but may represent any other system L substrate that is also 
concentrated by system A, as is Phe itself. BCH is also transported by system L. Either Phe 
or BCH inhibits the exodus of G through system L. 
These effects are illustrated in the diagram of Figure 4. The parallel operation of 
two transport  systems is shown for an amino acid that is pumped into the celt by a 
strongly concentrative transport system, such as system A. System L, generally 
being weakly concentrative, is forced to operate for net exodus by the high amino 
acid concentration attained inside the cell through the action of the Na+-dependent 
systems (Christensen, 1986; 1987a; 1987b; Christensen and Handlogten,  1979). In 
fact, it has been observed in this laboratory that the usually specific system A 
inhibitor, 2-aminoisobutyric acid, or its more uniformly specific N-methyl deriva- 
tive, causes decreases of the hepatic levels of amino acids relative to their plasma 
levels (Christensen and Cullen, 1968), whereas the relatively specific system L 
inhibitor, BCH,  causes corresponding increases (Christensen and Cullen, 1981). 
Phe, as well as other amino acids preferring system L for passage, has been shown 
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to increase the distribution ratio, tissue/plasma, for Gly in the liver and in the thigh 
muscle of the guinea pig (Christensen et al., 1948). 
At the level of the blood-brain barrier, however, system L was long the only 
transport system clearly recognized to function for neutral amino acids, the inward 
operation of system A at this site being apparently negligible (Wade and Katzman, 
1975; Betz and Goldstein, 1978). Therefore, Phe or similar system L substrates 
will, we hold, tend to decrease the brain/plasma distribution ratio of a number of 
amino acids by transport competition. 
In the present study, in all cases except that of Lys in liver, a statistically 
significant increase in distribution ratio after Phe injection was always accompanied 
by a statistically significant decrease in the plasma concentration of the correspond- 
ing amino acid (Table 2). Ala and Pro in liver and muscle, respectively, were the 
only two cases where an increase in net intracellular concentration accompanied 
their respective opposite changes in both plasma levels and distribution ratios. 
Only Glu- in muscle showed a statistically significant increase in the intracellular 
concentration without any other significant change (Table 2, column 4). 
The effect of Phe in increasing the distribution ratios of Ala and Gly in liver and 
also those of Ala, Gly and Pro in muscle (Table 2, column 4) is produced also by 
the system L analogue, aBCH, for Ala and Gly and probably also for Pro in muscle 
(Table 2, column 7; Figure 3) as well as for Ala in liver (Table 2, column 6). We 
think that these results can be explained by the mechanism discussed above. Ala, 
Gly and Pro, as preferred substrates of system A, are accumulated into the cells 
by this route and then the elevated intracellular Phe (Table 1) inhibits their exodus 
through system L. In a parallel effect to the one observed for Phe, aBCH caused 
a statistically significant decrease in the plasma concentration of Gly accompanying 
the increase in the distribution ratio of this amino acid in muscle. Although the 
decreases in the plasma concentrations of Ala and Pro after the administration of 
aBCH failed to show statistical significance, on the basis of their increased tissue/ 
plasma ratios attained, we think that this trapping effect is a likely contributory 
mechanism for the decrease of these two amino acids in plasma in hyperphenylalan- 
inaemia. It appears to be a major mechanism for the decrease in the plasma 
concentration of Gly under that condition. Previous results in this laboratory when 
Phe was fed to weanling rats at 5% in the diet for 6 days support the same conclusion 
(Christensen, 1987b). 
The statistically significant decrease in the net intracellular concentration of Gly 
in liver after aBCH injection can best be explained by its rapid catabolism through 
increased mass action arising from strong inhibition of exodus. A similar effect may 
explain the tack of increase in net intraceltular concentrations of other affected 
amino acids. 
We have no compelling explanation at this time for the statistically significant 
increases by Phe of the distribution ratios in muscle of other amino acids, namely 
Leu and His and the cationic amino acids, Orn and Arg, all of which also showed 
a statistically significant decrease in plasma. The apparent parallelism in the effects 
of Phe and aBCH on Lys in liver (Table 2, columns 3 and 6) and Arg in muscle 
(Table 2, Columns 4 and 7) deserves, however, further study (see Oldendorf et al., 
1988). 
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It is not clear why the unexplained accumulations of various amino acids in non- 
brain tissues of newborn rats treated with Phe and c~-MePhe observed by Huether 
and colleagues (1984) are seen only in the first perinatal days. These authors 
propose that the consequent depletion in plasma is the main factor contributing to 
the unavailability of amino acids to the brain and speculate that no competitive 
transport effects of Phe occur either at the blood-brain barrier (Huether et al., 
1984) or elsewhere (Huether, 1987). We think that a direct effect of Phe on the 
blood-brain barrier need not be excluded in proposing a separate likely contributory 
effect of the sequestration in other tissues on the depletion of amino acids in the 
brain in hyperphenylalaninaemic states. Neither does an increased utilization of 
certain amino acids exclude transport effects of the kind we are describing here for 
muscle and liver. Moreover, these transport effects may prove to be the first step 
that leads to an increased utilization of the trapped amino acid by mass action, as 
is probably the case for Gly in liver as illustrated in this study (Table 2, columns 
3 and 6). 
We propose instead that Phe causes a depletion of neutral amino acids in the 
brain by means of a dual competitive effect, one affecting directly the entry 
especially of bulky neutral amino acids at the level of the blood-brain barrier, and 
another, according to the results in this study, inhibiting the exodus of small neutral 
amino acids from non-brain tissues. 
Transport mechanisms in non-brain tissues have been proposed but not exper- 
imentally tested to explain the decrease in the plasma concentrations of isoleucine 
and valine after oral (Nyhan et al., 1961) and intravenous (Erikson et aI., 1981) 
loads of leucine in humans. On the specific question faced here, Efron and 
colleagues (1969), on the basis of the already known inhibitory effect of Phe on 
the entry of some amino acids into the brain, excluded transport effects as an 
explanation for the decrease of plasma amino acids in PKU. It was not fully 
understood at that time, however, that a specific transport system tends to be given 
directionality in its operation by the flows of metabolism in various tissues. 
Insulin concentrations in plasma have been found to be increased in PKU patients 
after a glucose load (Antonozzi et al., 1987). In fact, Phe is an effective insulin 
secretagogue in man (Fajans et al., 1967), although it appears be a very weak one 
in the rat, according to studies in the perfused pancreas (Landgraff et al., 1974) 
and also according to preliminary observations in our laboratory. In the present 
study, we purposely used a non-insulinogenic species of BCH, the a(_+) isomer 
(Tager and Christensen, 1971). Hence, the effect of Phe on the small neutral amino 
acids observed here seems to be related mainly to direct transport competitive 
effects. System A proves, however, a selective target of insulin in stimulation of 
amino acid transport in isolated preparations of rat liver and muscle (Shotwell et 
al., 1983). Even if secreted to a slightly increased extent in the pretreated rat, 
insulin could play a role to enhance the trapping effect by some administered amino 
acids described above. In man, the plasma levels of the branched-chain amino acids 
fell most during regulated insulin administration, although Pro and Ile were the 
most sensitive to insulin dose (Fukagawa et aI., 1986). We are currently exploring 
possible contributory effects of insulin in the changes of plasma and tissue amino 
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acids observed here, as well as after administration of Leu, the latter a clear insulin 
secretagogue in the rat (Landgraff et al., 1974). 
It is apparent in this study that the small neutral amino acids are the most 
generally affected. Experimental studies by others have also shown significant 
changes in several small neutral amino acids after Phe treatment. Ala has been 
found to be the most severely depleted of the non-essential amino acids in the 
brain of hyperphenylalaninaemic 10-day-old rats (Lowden and LaRamee, 1969), 
although the occasionally overlooked brain metabolism of branched chain amino 
acids also received appropriate emphasis in these results. Gly uptake into rat liver 
and brain has been found to be stimulated by Phe in short-term experiments (Zanic- 
Grubisic and Lipovac, 1981). The relationship of these effects to our findings is, 
however, not clear at this time. 
Ala, Gly and Pro are non-essential according to the classical meaning of this 
term. The possibility that the brain may need to receive non-essential amino acids 
supplied by other tissues must, however, not be overlooked. This point brings us 
to the subject of interorgan nutrition (Christensen, 1987b; 1982). For example, in 
discussing the availability of neurotransmitters in PKU, it is natural to think first 
only of Trp and Tyr. It is not known, however, if a shortage in the supply of blood 
Gly may also affect the concentration and further function of this neurotransmitter 
in the brain (Sershen et al., 1987). The exaggerated classical concept of essentiality 
of amino acids was so ingrained at the time of the publication of Linneweh 
and Ehrlich's paper that the non-essential amino acids were excluded from the 
calculations (1962 Figure 2). 
The significance of the present results to an understanding of the pathogenesis 
of the brain damage in PKU has to be assessed by further work. We are currently 
looking for changes in amino acid distribution in rats treated chronically with Phe 
and a-MePhe. A better animal model of PKU would, however, still be highly 
desirable. Complete plasma amino acid analysis in PKU patients at some times 
during treatment and at different metabolic states may also be enlightening to 
explain the significance of changes in other amino acids aside from Phe and Tyr in 
PKU. 
It may be relevant that under our relatively acute experimental as well as more 
prolonged (Christensen, 1987b) conditions, we have observed a pattern of plasma 
amino acids very similar to the one reported in PKU children (Figure 2; Linneweh 
and Ehrlich, 1962; Efron et al., 1969). As far as we are aware, the plasma amino 
acid pattern characteristic of PKU had not previously been reproduced in animals 
(Dolan and Golin, 1967; Kaufman, 1977). It may also be relevant that Efron and 
colleagues (1969) found an enhanced decrease of the amino acids affected in plasma 
in two of their PKU patients after an intravenous infusion of Phe. The differences 
were, however, also statistically significant when the patients were in their chronic 
condition, as was also apparently the case in the patients of Linneweh and Ehrlich 
(1962). On the other hand, Snyderman and colleagues (1981), in measuring several 
amino acids in fasting newborn PKU patients, found that only Thr showed a 
statistically significant decrease in the plasma, although Ala and also Arg were 
decreased along with Thr in the cerebrospinal fluid. Age of the patients and length 
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of fasting before sampling may be likely causes for the discrepancy between the 
different groups of PKU patients. Unfortunately, Thr always co-eluted with Ser in 
our analyses. 
Small neutral amino acids are also, in general, prominently depleted in plasma 
in PKU (Figure 2). Ala, Pro and Gly were found to be sharply decreased in the 
Linneweh and Ehrlich study, but, as noted above, the significance of the changes 
was not assessed statistically. On the other hand, Ala and Pro were found to be 
significantly decreased in plasma in the study of Efron and colleagues; Gly showed 
a p value of 0.05 as well as an additional decrease after Phe infusion (Efron et al., 
1969). Moreover, Ala together with Gln and Asn have been considered to be the 
only 'non-essential' amino acids whose depressed concentrations in plasma are 
corrected during the usual dietary treatment of PKU (Perry et al., 1970). In the 
present study, Gln, once considered an importantly depleted amino acid in PKU 
(Perry et al., 1970), was found to be decreased in plasma, although not to a 
statistically significant level (p = 0.17) (Table 1). Although significantly decreased 
in plasma in PKU patients, Gln was one of the less effected amino acids in the 
study of Efron and colleagues (1969). Under our experimental conditions, we did 
not find statistically significant changes either in the distribution ratio or in the 
intracellular concentration of Gtn in both liver and muscle (Tables 1 and 2). 
Perturbed transport processes are likely to be a prime cause of the deleterious 
imbalances in PKU and related inborn errors of amino acid metabolism. The 
identification of the transport mechanisms involved may be relevant to the possi- 
bility of specific interventions through the administration of selected amino acids 
or even relatively inert amino acid analogues. Such a step might help to correct 
the imbalances and may also have the additional benefit of allowing a less stringent 
and more palatable diet. Although this approach has been proposed by other 
investigators (Brunner et aI., 1979; Pratt, 1980), the focus previously has been 
directed exclusively to the brain and to the classical essential amino acids. We urge 
that, under our working hypothesis, other tissues and the amino acids usually 
considered as non-essential receive attention. 
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